(UroToday.com) Laurence Klotz, MD, FRCSC, gave a presentation elaborating on how to reduce the morbidity and improve the outcomes of androgen deprivation therapy (ADT) at the American Urological Association (AUA) 2020 Virtual Annual Meeting.
The objectives of this talk were to understand the long-term effects of ADT and its association with cardiac disease, metabolic syndrome, bone health, cognitive function, and quality of life. Dr. Klotz also planned to review the importance of serum testosterone levels in men receiving ADT. Additional goals of this talk included a comparison of intermittent versus continuous ADT use in prostate cancer patients, and discussing the role of ADT in the androgen receptor antagonist therapy (ARAT) era.